title: Different adaptations in AMPA receptor transmission in the nucleus accumbens after short vs long access cocaine self-administration regimens.
abstract: Ca(2+)-permeable AMPA receptors (CP-AMPARs) accumulate in the nucleus accumbens (NAc) after ∼1 month of withdrawal from a long-access cocaine self-administration regimen (6 h/d, 10d). This is functionally significant because CP-AMPARs mediate the 'incubated' cue-induced cocaine craving produced by this regimen. Our present goal was to determine if other commonly employed cocaine self-administration regimens also elicit CP-AMPAR accumulation. We compared four regimens, named according to whether sessions were short-access (ShA, 2 h) or long-access (LgA, 6 h) and the total number of sessions: LgA/10d (already shown to elicit CP-AMPAR accumulation), ShA/11d, ShA/20-24d, and LgA/20-24d. In the latter regimens, rats began with 10 days of ShA and then entered a differential phase (10-14 days) in which ShA sessions either continued or switched to LgA. Controls self-administered saline. After >40 days of withdrawal, whole-cell patch-clamp recordings were performed in NAc core medium spiny neurons to assess the contribution of CP-AMPAR transmission, based on the magnitude of synaptic suppression elicited by bath application of the selective CP-AMPAR antagonist naspm (100 μM). Naspm produced a non-significant (∼10%) attenuation of electrically evoked local excitatory postsynaptic current in the saline and ShA groups. By contrast, a significant naspm-induced synaptic attenuation (25-30%) was observed in both the LgA groups. Further analyses indicate that this emergence of CP-AMPAR transmission in the LgA groups is associated with increased baseline responsiveness of MSN to excitatory drive. Together with data on cocaine infusions in each group, our results show that CP-AMPAR accumulation and enhanced glutamate transmission is associated with longer sessions (6 h), rather than the number of sessions or cocaine infusions.
authors.affiliation: Department of Neuroscience, Rosalind Franklin University of Medicine and Science, The Chicago Medical School, North Chicago, IL, USA.
authors.forename: Anthony
authors.initials: A
authors.lastname: Purgianto
authors.forename: Andrew F
authors.initials: AF
authors.lastname: Scheyer
authors.forename: Jessica A
authors.initials: JA
authors.lastname: Loweth
authors.forename: Kerstin A
authors.initials: KA
authors.lastname: Ford
authors.forename: Kuei Y
authors.initials: KY
authors.lastname: Tseng
authors.forename: Marina E
authors.initials: ME
authors.lastname: Wolf
mesh_terms: D000818:Animals; D003042:Cocaine / Q000008:administration & dosage / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009714:Nucleus Accumbens / Q000378:metabolism*; D051381:Rats; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000502:physiology*; D012646:Self Administration; D013096:Spermine / Q000031:analogs & derivatives / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018091:Receptors, AMPA; C067506:1-naphthylacetylspermine; D013096:Spermine; D003042:Cocaine
references.citation: Neuropsychopharmacology. 2012 Jun;37(7):1671-82
references.pmid: 22414814
references.citation: Psychopharmacology (Berl). 1999 Oct;146(3):303-12
references.pmid: 10541731
references.citation: Science. 1998 Oct 9;282(5387):298-300
references.pmid: 9765157
references.citation: Neuron. 2007 Jun 21;54(6):859-71
references.pmid: 17582328
references.citation: Trends Neurosci. 2010 Sep;33(9):391-8
references.pmid: 20655604
references.citation: Nature. 2008 Jul 3;454(7200):118-21
references.pmid: 18500330
references.citation: Brain Res. 2011 Jan 7;1367:223-33
references.pmid: 20946890
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):389-94
references.pmid: 17113207
references.citation: Science. 2004 Aug 13;305(5686):1014-7
references.pmid: 15310906
references.citation: Neurosci Biobehav Rev. 2010 Nov;35(2):185-211
references.pmid: 20109488
references.citation: Neuroscience. 2009 Mar 3;159(1):414-26
references.pmid: 19105975
references.citation: Neuropharmacology. 2011 Dec;61(7):1141-51
references.pmid: 21276808
references.citation: Front Mol Neurosci. 2012 Feb 13;5:17
references.pmid: 22347846
references.citation: Neuropsychopharmacology. 2011 Mar;36(4):871-8
references.pmid: 21160464
references.citation: Nat Neurosci. 2009 Aug;12(8):1036-41
references.pmid: 19597494
references.citation: J Pharmacol Exp Ther. 2007 Sep;322(3):1103-9
references.pmid: 17601982
references.citation: J Neurosci. 2007 Jul 25;27(30):7921-8
references.pmid: 17652583
references.citation: Psychopharmacology (Berl). 2006 Jul;187(1):60-7
references.pmid: 16598453
references.citation: J Neurosci. 2010 Jun 9;30(23):7984-92
references.pmid: 20534846
references.citation: Curr Drug Abuse Rev. 2009 May;2(2):184-94
references.pmid: 19630748
references.citation: Behav Neurosci. 2009 Aug;123(4):913-25
references.pmid: 19634952
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):863-9
references.pmid: 18281138
references.citation: Synapse. 2009 Jul;63(7):598-609
references.pmid: 19306440
references.citation: J Neurosci. 2011 Oct 12;31(41):14536-41
references.pmid: 21994370
references.citation: Biol Psychiatry. 2005 Nov 1;58(9):751-9
references.pmid: 16098484
references.citation: Trends Neurosci. 2011 Aug;34(8):411-20
references.pmid: 21764143
references.citation: J Neurosci. 2011 Apr 13;31(15):5737-43
references.pmid: 21490215
references.citation: Psychopharmacology (Berl). 2008 Jan;195(4):591-603
references.pmid: 17899015
references.citation: J Neurosci. 2007 Sep 26;27(39):10621-35
references.pmid: 17898233
references.citation: Nat Neurosci. 2011 Apr;14(4):414-6
references.pmid: 21336270
references.citation: Neuropsychopharmacology. 2010 Feb;35(3):818-33
references.pmid: 19924109
references.citation: Science. 2004 Aug 13;305(5686):1017-9
references.pmid: 15310907
references.citation: Curr Opin Neurobiol. 2013 Aug;23(4):500-6
references.pmid: 23385114
references.citation: Nat Neurosci. 2009 Feb;12(2):182-9
references.pmid: 19136971
references.citation: Pharmacol Biochem Behav. 2012 Feb;100(4):801-10
references.pmid: 21536062
references.citation: Neuroreport. 2003 Dec 2;14(17):2229-32
references.pmid: 14625453
references.citation: Neuropharmacology. 2004;47 Suppl 1:214-26
references.pmid: 15464139
references.citation: J Neurosci. 2012 Sep 5;32(36):12406-10
references.pmid: 22956831
references.citation: Front Mol Neurosci. 2012 Jun 27;5:72
references.pmid: 22754497
references.citation: Psychopharmacology (Berl). 2004 Aug;175(1):26-36
references.pmid: 15042275
references.citation: Am J Psychiatry. 2005 Aug;162(8):1403-13
references.pmid: 16055761
references.citation: J Neurosci. 2011 Nov 9;31(45):16177-84
references.pmid: 22072669